Penn Rodebaugh Diabetes Center Trials
|
|
Andrea Kelly, MD, MSCE & Michael Rickels, MD, MS
|
Determination of Beta-Cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis |
| Andrea Kelly, MD, MSCE & Michael Rickels, MD, MS |
Emergence and Progression of Abnormal Glucose Tolerance in Cystic Fibrosis |
| Andrea Kelly, MD, MSCE & Michael Rickels, MD, MS |
Effects of GLP-1 Agonist Therapy on Insulin Secretion in Adults with Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a randomized, open-label, cross-over trial |
| Ali Naji, MD & Michael Rickles, MD, MS |
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in
Subjects Who Have Type 1 Diabetes Mellitus with Impaired Hypoglycemic
Awareness and Severe Hypoglycemia |
| James Markmann, MD, PhD and Michael Rickels, MD |
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus |
| Michael Rickels, MD, MS |
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline |
| Michael Rickels, MD, MS |
2IQP: A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ Technology in Adults with Type 2 Diabetes Using Basal-Bolus Insulin Therapy |
| Michael Rickels, MD, MS |
Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults with Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a randomized, open-label, cross-over trial |
| Michael Rickels, MD, MS & Zoltan Arany, PhD |
Effect of Branched Chain Amino Acids on Free Fatty Acid-Induced Insulin Resistance in Healthy Adults. |
|
Mark Schutta, MD
|
Epidemiology of Diabetes Interventions and Complications Study (EDIC STUDY)
|
Penn Bone Center Trials
|
| Mona Al Mukaddam, MD, MS |
A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants 5 years of age and older (FALKON) |
| Mona Al Mukaddam, MD, MS |
Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit from Palovarotene Therapy. (PIVOINE) |
| Mona Al Mukaddam, MD, MS |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (PROGRESS) |
| Felix Wehrli, PhD |
Bone Water and Mineralization Measured by Nuclear Magnetic Resonance |
Penn Metabolic Medicine Trials
|
| Anastastia Amaro, MD |
A Prospective, Randomized, Double-Blind, Sham- Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin therapy |
| Kelly Allison, PhD |
Meal Timing and Metabolism Study |
| Zoltan P. Arany, M.D., Ph.D., Michael R. Rickels, MD., MS |
Investigation of the Effect of Branched Chain Amino Acids on Fat-Induced Insulin Resistance in Healthy Adults |
|
David Merrick, MD, PhD
|
Human Metabolic Tissue Bank
|
Penn Pituitary Center Trials
|
| Peter Snyder, MD |
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands |
Penn Thyroid Center Trials
|
|
Anne Cappola, MD, MS
|
Ghrelin Plus Resistance Training in Frail Elderly Study
|
| |
|
| |
|